Loading clinical trials...
Loading clinical trials...
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD
Conditions
Interventions
ABBV-RGX-314 Dose 1
ABBV-RGX-314 Dose 2
+1 more
Locations
181
United States
Barnet Dulaney Eye Center-Phoenix /ID# 256340
Phoenix, Arizona, United States
Retinal Research Institute /ID# 256238
Phoenix, Arizona, United States
Retina Macula Institute of Arizona /ID# 271026
Scottsdale, Arizona, United States
California Retina Consultants - Bakersfield /ID# 256240
Bakersfield, California, United States
Retina Vitreous Assoc Med Grp /ID# 256246
Beverly Hills, California, United States
Retinal Diagnostic Center /ID# 256262
Campbell, California, United States
Start Date
January 13, 2022
Primary Completion Date
October 1, 2026
Completion Date
November 1, 2027
Last Updated
April 20, 2026
NCT07308639
NCT05562947
NCT05547633
NCT06859515
NCT06925893
NCT06718816
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions